Schering-Plough Reports Financial Results for 2009 Seco... (wing that a greater proportion of anti-T...)

Schering-Plough Reports Financial Results for 2009 Second Quarter

Date:7/21/2009

wing that a greater proportion of anti-TNF-experienced patients with moderately to severely active rheumatoid arthritis who received subcutaneous injections of SIMPONI every four weeks experienced significant improvements in signs and symptoms compared with patients receiving placebo. (Announced June 10)

With Merck, reported the receipt of a request for additional information from the U.S. Federal Trade Commission with respect to the previously announced proposed merger. (Announced June 22)

Santarus, Inc. announced that Schering-Plough HealthCare Products, Inc. had received notification from the FDA of a December 2009 action date for an over-the-counter ZEGERID branded omeprazole/sodium bicarbonate product. (Announced June 23)

Schering-Plough and Merck scheduled special meetings of shareholders on Aug. 7, 2009, for purposes of voting on the proposed merger. The transaction is subject to shareholder approvals as well as the satisfaction of customary closing conditions and regulatory approvals, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, as well as clearance by the European Commission under the EC Merger Regulation and certain other foreign jurisdictions. (Announced June 25)

Reported results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days. (Announced July 1)

Extended to stage two an ongoing Phase II clinical study with vicriviroc, an investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. (Announced July 15)

Merck and Schering-Plough and the companies' cholesterol joint venture, Merck/Sch

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma

Post Your Comments:

Schering-Plough Reports Financial Results for 2009 Seco...(wing that a greater proportion of anti-T...)